抗心律失常药物现代分类:Vaughan Williams 框架百年更新
在 Vaughan Williams 抗心律失常药物分类诞生百年之际,作者综述了关于肌膜、肌浆网和胞质生物分子的后续发现,保留原 I–IV 类并依据新进展进行亚类划分,同时基于自动性相关通道、机械敏感离子通道、连接蛋白及长期结构重构信号分子等新靶点引入新类别,形成兼顾多重靶点与不良反应的实用分类框架。
要点
- 保留 Vaughan Williams 原 I–IV 类,并依据 Na+ 电流成分、自主神经信号、K+ 通道亚型、Ca2+ 稳态靶点进行亚类划分。
- 新增基于自动性相关通道、机械敏感离子通道、连接蛋白及长期结构重构信号分子的药物类别。
- 新分类允许药物存在多重靶点与作用,并涵盖不良甚至致心律失常效应,也便于归类在研新药。
核心结论
- 提出保留原框架简洁性的现代化抗心律失常药物分类,有助于理解和管理心律失常事件并促进该领域未来发展。
研究设计与样本
- 综述:基于 Vaughan Williams 原始分类,调查后续关于肌膜、肌浆网和胞质生物分子的发现,构建涵盖已批准和潜在抗心律失常药物的扩展分类。
主要发现
- 保留原 Vaughan Williams I–IV 类,并依据 Na+ 电流成分(I 类)、自主神经(常为 G 蛋白介导)信号(II 类)、K+ 通道亚型(III 类)、Ca2+ 稳态相关新分子靶点(IV 类)进行亚类划分。
- 基于额外靶点引入新类别,包括参与自动性的通道、机械敏感离子通道、控制电紧张性细胞耦联的连接蛋白、以及影响结构重构的长期信号过程分子。
- 修订分类允许药物存在多重靶点/作用,并涵盖不良、有时致心律失常的效应,也有助于对在研新药进行分类。
临床怎么用
- 临床可依据药物靶点及多重作用理解抗心律失常药物的疗效与致心律失常风险,并用于新药归类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among his major cardiac electrophysiological contributions, Miles Vaughan Williams (1918-2016) provided a classification of antiarrhythmic drugs that remains central to their clinical use. METHODS: We survey implications of subsequent discoveries concerning sarcolemmal, sarcoplasmic reticular, and cytosolic biomolecules, developing an expanded but pragmatic classification that encompasses approved and potential antiarrhythmic drugs on this centenary of his birth. RESULTS: We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects. We retain the original Vaughan Williams Classes I through IV but subcategorize these divisions in light of more recent developments, including the existence of Na+ current components (for Class I), advances in autonomic (often G protein-mediated) signaling (for Class II), K+ channel subspecies (for Class III), and novel molecular targets related to Ca2+ homeostasis (for Class IV). We introduce new classes based on additional targets, including channels involved in automaticity, mechanically sensitive ion channels, connexins controlling electrotonic cell coupling, and molecules underlying longer-term signaling processes affecting structural remodeling. Inclusion of this widened range of targets and their physiological sequelae provides a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation. CONCLUSIONS: We emerge with a modernized classification preserving the simplicity of the original Vaughan Williams framework while aiding our understanding and clinical management of cardiac arrhythmic events and facilitating future developments in this area.
引用
- Lei M, Wu L, Terrar DA, et al. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018. PMID: 30354657. doi:10.1161/CIRCULATIONAHA.118.035455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。